BFCH to Acquire EVERMIND™ Beverage, Strengthening Cognitive Health Portfolio
TL;DR
BitFrontier Capital Holdings acquires ERApeutics, LLC, enhancing its portfolio with EVERMIND™, a cognitive health beverage, positioning for growth and institutional investment.
The acquisition involves a $4,000,000 equity deal, issuing 400,000,000 shares at $0.01 each, strengthening BFCH's balance sheet and supporting its OTCQB uplisting strategy.
EVERMIND™ aims to improve mental clarity and cognitive performance, contributing to a healthier society with its science-backed, plant-based functional beverage.
Discover EVERMIND™, a revolutionary cognitive health beverage, as BFCH expands into the wellness sector with a unique, IP-backed product ready for the market.
Found this article helpful?
Share it with your network and spread the knowledge!
BitFrontier Capital Holdings, Inc. (OTC: BFCH), operating as EVERMIND Holdings, Inc., has entered into a binding Letter of Intent (LOI) to acquire ERApeutics, LLC, the creator of the EVERMIND™ beverage platform. This acquisition, valued at $4,000,000 through the issuance of 400,000,000 restricted common shares at $0.01 per share, signifies BFCH's commitment to expanding its footprint in the cognitive health and wellness sector. EVERMIND™, a physician-formulated, plant-based protein shake, is designed to support brain health with both immediate and long-term benefits, backed by scientific research and ready for commercial launch.
The EVERMIND™ platform includes six proprietary nootropic and adaptogenic formulations, alongside a robust R&D pipeline, academic research, and registered trademarks. With a fully integrated e-commerce system via thinkevermind.com, the brand is poised for rapid market entry. The acquisition not only adds significant intellectual property and assets to BFCH's portfolio but also aligns with the company's strategy to uplist to the OTCQB market, following the elimination of over $2 million in toxic convertible debt and reducing total liabilities to under $94,000.
Dr. Jordan Balencic, CEO of BFCH, emphasized the strategic importance of EVERMIND™, comparing its potential impact on cognitive health to that of Celsius in the metabolic health space. The functional beverage market, witnessing significant investments from major players like Keurig Dr Pepper and Coca-Cola, presents a lucrative opportunity for BFCH to capitalize on the growing demand for wellness-oriented products. The transaction, expected to close within 60 to 90 days, will see EVERMIND™ operating as a wholly owned subsidiary of EVERMIND Labs, with potential for future spin-offs.
This move by BFCH underscores the increasing institutional interest in the functional beverage sector, particularly those offerings that combine health benefits with consumer convenience. EVERMIND™'s focus on cognitive performance, mood, and mental clarity positions it uniquely within this competitive landscape, offering a scalable and scientifically validated product that meets the evolving needs of health-conscious consumers.
Curated from NewMediaWire
